Recombinant Porcine PD-1 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10484-PD

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10484-PD-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

NP_001191308.1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all PD-1 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived porcine PD-1 protein
Porcine PD-1
(Leu25-Gln169)
Accession # NP_001191308.1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Leu25

Predicted Molecular Mass

43 kDa

SDS-PAGE

60-75 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Porcine PD‑1 Fc Chimera (Catalog # 10484-PD) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human PD-L1/B7‑H1 Fc Chimera  (Catalog # 156-B7) that produces a 50% optimal binding response is found to be 0.03-0.3 µg/mL.

Scientific Data Images for Recombinant Porcine PD-1 Fc Chimera Protein, CF

Recombinant Porcine PD-1 Fc Chimera Protein Binding Activity

Recombinant Porcine PD-1 Fc Chimera Protein Binding Activity

When Recombinant Porcine PD‑1 Fc Chimera (10484-PD) is immobilized at 1 µg/mL (100 µL/ well), Recombinant Human PD-L1/B7‑H1 Fc Chimera (156-B7) that produces a 50% optimal binding response is found to be 0.03-0.3 µg/mL
Recombinant Porcine PD-1 Fc Chimera Protein SDS-PAGE

Recombinant Porcine PD-1 Fc Chimera Protein SDS-PAGE

2 μg/lane of Recombinant Porcine PD-1 Fc Chimera Protein (10484-PD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-75 kDa and 120-150 kDa, respectively.

Formulation, Preparation and Storage

10484-PD
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: PD-1

Programmed Death-1 receptor (PD-1), also known as CD279, is type I transmembrane protein belonging to the CD28 family of immune regulatory receptors (1). Other members of this family include CD28, CTLA-4, ICOS, and BTLA (2-5). PD-1 consists of an extracellular domain (ECD) with one immunoglobulin-like V-type domain, a transmembrane domain, and a cytoplasmic region with two tyrosine resideus. These tyrosine residues form the immunoreceptor tyrosine-based inhbitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) tha are important for mediating PD-1 signaling. The extracellular domain (ECD) of porcine PD-1 shares 68% and 60% amino acid sequence identity with the human and rat PD-1, respectively. PD-1 acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (6, 7). PD-1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and on non-hematopoietic cells such as lung endothelial cells and hepatocytes (8, 9). Ligation of PD-L1 with PD-1 induces co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion (10). Thus, the PD-1: PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance (11). Blockade of the PD-1: PD-L1 interaction by either antibodies or genetic manipulation accelerates tumor eradication and shows potential for improving cancer immunotherapy (12-14).

References

  1. Ishida, Y. et al. (1992) EMBO J. 11:3887.
  2. Sharpe, A.H. and G. J. Freeman (2002) Nat. Rev. Immunol. 2:116.
  3. Coyle, A. and J. Gutierrez-Ramos (2001) Nat. Immunol. 2:203.
  4. Nishimura, H. and T. Honjo (2001) Trends Immunol. 22:265.
  5. Watanabe, N. et al. (2003) Nat. Immunol. 4:670.
  6. Zhang, X. et al. (2004) Immunity 20:337.
  7. Lázár-Molnár, E. et al. (2008) Proc. Natl. Acad. Sci. USA 105:10483.
  8. Nishimura, H et al. (1996) Int. Immunol. 8:773.
  9. Keir, M.E. et al. (2008) Annu. Rev. Immunol. 26:677.
  10. Butte, M.J. et al. (2007) Immunity 27:111.
  11. Okazaki, T. et al. (2013) Nat. Immunol. 14:1212.
  12. Iwai, Y. et al. (2002) Proc. Natl. Acad. Sci. USA 99:12293.
  13. Nogrady, B. (2014) Nature 513:S10.
  14. Swaika, A. et al. (2015) Mol. Immunol. 67:4.

Long Name

Programmed Death-1

Alternate Names

CD279, PD1, PDCD1, SLEB2

Entrez Gene IDs

5133 (Human); 18566 (Mouse); 301626 (Rat); 100533201 (Porcine); 486213 (Canine); 102123659 (Cynomolgus Monkey)

Gene Symbol

PDCD1

UniProt

NP_001191308.1

Additional PD-1 Products

Product Documents for Recombinant Porcine PD-1 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Porcine PD-1 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.